...
首页> 外文期刊>Medical hypotheses >Neuroprotective potential of Piroxicam in cerebral ischemia: An in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a
【24h】

Neuroprotective potential of Piroxicam in cerebral ischemia: An in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a

机译:吡罗昔康在脑缺血中的神经保护潜力:对该假说的计算机评估,以通过抑制水通道蛋白4和酸感应离子通道1a探索其治疗功效

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cerebral stroke is caused by acute interruption of the brain arterial blood supply and is one of the major health problems with no effective treatments so far apart from the thrombolytic recombinant tissue plasminogen activator (rt-PA), which must be administered within 3. h of stroke onset. This emerges it as the third leading cause of mortality worldwide. Acidosis and brain edema are the prominent metabolic features of ischemic brain. The combined inhibition of aquaporin-4 (AQP4) and ASIC1a channels may offers a new neuroprotective approach in cerebral stroke management. Moreover, the combined inhibition of AQP4 and ASIC1a with NSAID remains unknown against neuroprotection in animal models of cerebral ischemia. NSAIDs are believed to act as a pharmacological molecule that reported to have an antioxidant and anti-inflammatory properties. Therefore, the target of the present in silico study was to determine the neuroprotective efficacy of Piroxicam, a NSAID in animal model of cerebral ischemia/reperfusion (I/R) injury and efforts were made to analyze its inhibitory effects on aquaporin-4 activation and ASIC1a channels mediated downstream survival/damage mechanisms. Thus we hypothesized that Piroxicam, a NSAID can act as a neuroprotective agent in animal model of cerebral ischemia/reperfusion (I/R) injury due to its inhibitory effects on aquaporin-4 channel and ASIC1a channels. It is indeed vital that we do not give up the fight to develop compounds to treat stroke despite the many years of setbacks. One of the mottos of our proposed hypothesis is to find out a successful modality of effective substantial treatment of brain stroke with other anti stroke therapeutics available till date.
机译:脑卒中是由脑动脉​​血液供应的突然中断引起的,是主要的健康问题之一,除溶栓重组组织纤溶酶原激活剂(rt-PA)以外,尚无有效的治疗方法,必须在3小时内给予溶栓重组组织纤溶酶原激活剂。中风发作。这使其成为全球第三大死亡原因。酸中毒和脑水肿是缺血性脑的突出代谢特征。 Aquaporin-4(AQP4)和ASIC1a通道的组合抑制作用可能为脑卒中治疗提供一种新的神经保护方法。此外,在脑缺血的动物模型中,用NSAID联合抑制AQP4和ASIC1a对抗神经保护作用仍然未知。据信NSAIDs起药理学分子的作用,据报道具有抗氧化剂和抗炎特性。因此,本计算机研究的目标是确定非甾体抗炎药吡罗昔康(Piroxicam)在脑缺血/再灌注(I / R)损伤动物模型中的神经保护作用,并努力分析其对水通道蛋白4激活和抑制的抑制作用。 ASIC1a通道介导了下游生存/损害机制。因此,我们假设非甾体抗炎药吡罗昔康(Piroxicam)由于对水通道蛋白4通道和ASIC1a通道具有抑制作用,因此可以在脑缺血/再灌注(I / R)损伤的动物模型中充当神经保护剂。尽管经历了许多年的挫折,但我们绝不放弃为开发可治疗中风的化合物而进行的斗争,这一点确实至关重要。我们提出的假设的座右铭之一是找到一种有效的对脑卒中进行有效的实质性治疗的成功方式,迄今为止还可以使用其他抗中风疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号